Despite high efficacy of CAR T cells in reducing tumor load, nearly every second patient suffers from disease relapse (5) which is in most cases due to leukemic cells with downregulated or loss of CD19 resulting to antigen levels below the CAR T cell activation threshold, commonly termed as antigen escape (6). Here, CD19 is linked to neoplasm.